MD4710C1 - Tratamente terapeutice pe bază de anamorelin - Google Patents

Tratamente terapeutice pe bază de anamorelin Download PDF

Info

Publication number
MD4710C1
MD4710C1 MDA20170025A MD20170025A MD4710C1 MD 4710 C1 MD4710 C1 MD 4710C1 MD A20170025 A MDA20170025 A MD A20170025A MD 20170025 A MD20170025 A MD 20170025A MD 4710 C1 MD4710 C1 MD 4710C1
Authority
MD
Moldova
Prior art keywords
anamorelin
patient
cancer
patients
cachexia
Prior art date
Application number
MDA20170025A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD20170025A2 (ro
MD4710B1 (ro
Inventor
Уильям МЭНН
Джон ФРЕНД
Уильям ПОЛВИНО
Сьюзен АЛЛЕН
М Лу
Элизабет ДУУС
Энрико БАРОНИ
Рубен ДЖИОРДЖИНО
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4710(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MD20170025A2 publication Critical patent/MD20170025A2/ro
Publication of MD4710B1 publication Critical patent/MD4710B1/ro
Publication of MD4710C1 publication Critical patent/MD4710C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MDA20170025A 2014-09-04 2015-08-28 Tratamente terapeutice pe bază de anamorelin MD4710C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (3)

Publication Number Publication Date
MD20170025A2 MD20170025A2 (ro) 2017-07-31
MD4710B1 MD4710B1 (ro) 2020-09-30
MD4710C1 true MD4710C1 (ro) 2021-04-30

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20170025A MD4710C1 (ro) 2014-09-04 2015-08-28 Tratamente terapeutice pe bază de anamorelin

Country Status (44)

Country Link
US (5) US9675600B2 (Direct)
EP (2) EP3188599B1 (Direct)
JP (3) JP6356907B2 (Direct)
KR (3) KR102307275B1 (Direct)
CN (5) CN113577073A (Direct)
AP (1) AP2017009772A0 (Direct)
AR (1) AR103118A1 (Direct)
AU (1) AU2015312231B2 (Direct)
BR (1) BR112017003552A2 (Direct)
CA (1) CA2959158A1 (Direct)
CL (1) CL2017000494A1 (Direct)
CO (1) CO2017003263A2 (Direct)
CR (1) CR20170121A (Direct)
CY (1) CY1122746T1 (Direct)
DK (1) DK3188599T3 (Direct)
DO (1) DOP2017000055A (Direct)
EA (1) EA035578B1 (Direct)
EC (1) ECSP17019893A (Direct)
ES (1) ES2761777T3 (Direct)
GE (2) GEAP201814459A (Direct)
HR (1) HRP20192345T1 (Direct)
HU (1) HUE046894T2 (Direct)
IL (1) IL250692B (Direct)
JO (1) JO3541B1 (Direct)
LT (1) LT3188599T (Direct)
MA (1) MA40607B1 (Direct)
MD (1) MD4710C1 (Direct)
ME (1) ME03597B (Direct)
MX (1) MX361741B (Direct)
MY (1) MY187167A (Direct)
NI (1) NI201700024A (Direct)
PE (1) PE20171109A1 (Direct)
PH (1) PH12017500392B1 (Direct)
PL (1) PL3188599T3 (Direct)
PT (1) PT3188599T (Direct)
RS (1) RS59751B1 (Direct)
SG (1) SG11201701567UA (Direct)
SI (1) SI3188599T1 (Direct)
SV (1) SV2017005400A (Direct)
TN (1) TN2017000040A1 (Direct)
TW (1) TWI639429B (Direct)
UA (1) UA120765C2 (Direct)
UY (1) UY36286A (Direct)
WO (1) WO2016036598A1 (Direct)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
PL3188599T3 (pl) 2014-09-04 2020-06-01 Helsinn Healthcare Sa Zabiegi medyczne w oparciu o anamorelinę
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
CN114630655A (zh) 2019-08-30 2022-06-14 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
BR112022005457A2 (pt) 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
CN103772483A (zh) 2004-06-29 2014-05-07 赫尔辛医疗股份公司 （3r）－1－（2－甲基丙氨酰－d－色氨酰）－3－（苯甲基）－3－哌啶羧酸1,2,2－三甲基酰肼的晶形
MX2009008561A (es) * 2007-02-13 2010-01-15 Helsinn Therapeutics Us Inc Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
TW201400506A (zh) * 2012-05-25 2014-01-01 Raqualia Pharma Inc 用於治療胃酸缺乏症之生長激素釋放肽受體促效劑
PL3188599T3 (pl) 2014-09-04 2020-06-01 Helsinn Healthcare Sa Zabiegi medyczne w oparciu o anamorelinę

Also Published As

Publication number Publication date
AP2017009772A0 (en) 2017-02-28
PH12017500392A1 (en) 2017-07-17
HRP20192345T1 (hr) 2020-03-20
JP6923486B2 (ja) 2021-08-18
PL3188599T3 (pl) 2020-06-01
TW201613587A (en) 2016-04-16
ECSP17019893A (es) 2017-05-31
BR112017003552A2 (pt) 2017-12-05
US10278964B2 (en) 2019-05-07
SG11201701567UA (en) 2017-03-30
US20170296526A1 (en) 2017-10-19
LT3188599T (lt) 2019-12-10
KR20180085047A (ko) 2018-07-25
EP3590338A2 (en) 2020-01-08
HUE046894T2 (hu) 2020-04-28
US9675600B2 (en) 2017-06-13
IL250692B (en) 2019-05-30
CN113577074A (zh) 2021-11-02
ES2761777T3 (es) 2020-05-21
CN107375285A (zh) 2017-11-24
EP3590338A3 (en) 2020-03-18
KR102234319B1 (ko) 2021-04-01
SV2017005400A (es) 2017-04-20
CN109172575A (zh) 2019-01-11
MA40607B1 (fr) 2019-11-29
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
KR20210035923A (ko) 2021-04-01
US11723902B2 (en) 2023-08-15
MX2017002825A (es) 2017-09-28
PT3188599T (pt) 2020-01-15
US20190175574A1 (en) 2019-06-13
JP7044918B2 (ja) 2022-03-30
CO2017003263A2 (es) 2017-07-28
TWI639429B (zh) 2018-11-01
UA120765C2 (uk) 2020-02-10
SI3188599T1 (sl) 2020-02-28
EP3188599A1 (en) 2017-07-12
CN107205389A (zh) 2017-09-26
CN113577073A (zh) 2021-11-02
RS59751B1 (sr) 2020-02-28
KR102307275B1 (ko) 2021-09-30
JP2018154655A (ja) 2018-10-04
EP3188599A4 (en) 2017-10-11
KR20170047372A (ko) 2017-05-04
WO2016036598A1 (en) 2016-03-10
CA2959158A1 (en) 2016-03-10
NZ729673A (en) 2023-09-29
MD20170025A2 (ro) 2017-07-31
GEAP201814459A (en) 2018-09-10
CL2017000494A1 (es) 2017-09-15
EP3188599B1 (en) 2019-10-02
DOP2017000055A (es) 2017-08-15
US20240024303A1 (en) 2024-01-25
PE20171109A1 (es) 2017-08-07
KR101881264B1 (ko) 2018-07-23
JP2021080281A (ja) 2021-05-27
AU2015312231B2 (en) 2017-10-19
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
PH12017500392B1 (en) 2018-08-31
US10894041B2 (en) 2021-01-19
JP2017526695A (ja) 2017-09-14
US20160067236A1 (en) 2016-03-10
MX361741B (es) 2018-12-14
IL250692A0 (en) 2017-04-30
US20210093627A1 (en) 2021-04-01
CR20170121A (es) 2017-07-17
MD4710B1 (ro) 2020-09-30
AR103118A1 (es) 2017-04-19
JO3541B1 (ar) 2020-07-05
CY1122746T1 (el) 2021-03-12
JP6356907B2 (ja) 2018-07-11
ME03597B (me) 2020-07-20
NI201700024A (es) 2017-07-18
TN2017000040A1 (en) 2018-07-04
UY36286A (es) 2016-02-29
MY187167A (en) 2021-09-07
AU2015312231A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
MD4710C1 (ro) Tratamente terapeutice pe bază de anamorelin
Munoz et al. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines
Badran et al. Metabolic aspects of surgical subcutaneous fat removal: an umbrella review and implications for future research
Winkelmann et al. Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
Wang et al. IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells
Fogh et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies
Cha et al. Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer
HK40020876A (en) Medical treatments based on anamorelin
OA18229A (en) Medical treatments based on anamorelin.
HK1234959A1 (en) Medical treatments based on anamorelin
HK1234959B (en) Medical treatments based on anamorelin
Marcella et al. Low‐dose lithium supplementation promotes musculoskeletal and metabolic health in ovariectomized female mice
WO2023042158A1 (en) Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients
Hinzpeter Cohen et al. Gonyautoxins: First evidence in pain management in total knee arthroplasty
US20170252311A1 (en) Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma
Davis et al. CASE PRESENTATION A 47-year-old man developed shoulder pain that subsequently radiated to his little finger over 4 months and increased in sever-ity. He initially took nonsteroidal anti-inflammatory drugs (NSAIDs). His primary care physician ordered a chest X-ray (read
Spiegelberg et al. 1083 POSTER The Effects of Heparan Sulfate Mimetic RGTA-OTR4120 on Radiation-induced Salivary Gland Dysfunction in Mice

Legal Events

Date Code Title Description
FG4A Patent for invention issued